A detailed history of Cooper Financial Group transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Cooper Financial Group holds 4,031 shares of VRTX stock, worth $1.65 Million. This represents 0.25% of its overall portfolio holdings.

Number of Shares
4,031
Previous 3,747 7.58%
Holding current value
$1.65 Million
Previous $1.76 Million 6.72%
% of portfolio
0.25%
Previous 0.26%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$460.0 - $505.78 $130,640 - $143,641
284 Added 7.58%
4,031 $1.87 Million
Q2 2024

Jul 15, 2024

BUY
$392.81 - $485.53 $47,137 - $58,263
120 Added 3.31%
3,747 $1.76 Million
Q1 2024

Apr 11, 2024

BUY
$407.69 - $446.08 $163,076 - $178,432
400 Added 12.4%
3,627 $1.52 Million
Q4 2023

Jan 16, 2024

BUY
$343.0 - $410.68 $71,001 - $85,010
207 Added 6.85%
3,227 $1.31 Million
Q3 2023

Oct 13, 2023

BUY
$338.18 - $362.46 $9,807 - $10,511
29 Added 0.97%
3,020 $1.05 Million
Q2 2023

Jul 07, 2023

BUY
$314.42 - $351.91 $93,382 - $104,517
297 Added 11.02%
2,991 $1.05 Million
Q1 2023

May 10, 2023

BUY
$283.23 - $323.1 $65,142 - $74,313
230 Added 9.33%
2,694 $848,000
Q4 2022

Jan 13, 2023

BUY
$285.76 - $321.48 $133,164 - $149,809
466 Added 23.32%
2,464 $0
Q3 2022

Oct 13, 2022

BUY
$273.83 - $305.53 $251,102 - $280,171
917 Added 84.83%
1,998 $579,000
Q2 2022

Jul 11, 2022

BUY
$234.96 - $292.55 $28,665 - $35,691
122 Added 12.72%
1,081 $305,000
Q1 2022

Apr 12, 2022

BUY
$221.42 - $260.97 $4,871 - $5,741
22 Added 2.35%
959 $250,000
Q4 2021

Feb 11, 2022

BUY
$177.01 - $223.45 $165,858 - $209,372
937 New
937 $206,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Cooper Financial Group Portfolio

Follow Cooper Financial Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cooper Financial Group, based on Form 13F filings with the SEC.

News

Stay updated on Cooper Financial Group with notifications on news.